BiomX news
- Reducing headcount by 50% to further extend capital resources
- Cash runway extended to at least mid-2024
- Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the third quarter of 2022 and readout from part 2 of the study expected in the first quarter of 2023
- Atopic Dermatitis Program will be delayed due to restructuring
BiomX Inc. (NYSE American: PH
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics. The research was conducted by scientists at BiomX and is available
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, May 11, 2022, at 8:00 a.m. EDT, to report first quarter 2022 financial results and provide business updates. To partici
- Funding Will Support Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Respiratory Infections in CF Patients
- CF Foundation to Invest up to $5 Million in BiomX Common Stock
- Data Readouts from Phase 1b/2a CF Trial of BX004 Expected in 2022
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomX’s atopic dermatitis product candidate, BX005, in Japan. The right of first offer will comm
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX005 in atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (“RAD”) 2021 Virtual Conference and will also be presented at the upcoming International Conference on Phage Therapy and Bacteriophages. R